Client News

InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904

Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada

AFYREN and ESSE Skincare begin partnership to offer 100% natural cosmetic solutions with enhanced skincare performance

Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)

AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101 for the Treatment of ALS, Supporting Plans for a Confirmatory Phase 3 Study

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025

Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region

DoctorBox Adds Mainz Biomed’s ColoAlert® to Its Portfolio DNA-based Colorectal Cancer Screening as a Home Test

Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions

Tacalyx Appoints Jean Engela as Chief Executive Officer to Spearhead Next Phase of Growth